Bayer HealthCare Pharmaceuticals announced the results of three clinical studies with Betaseron? (interferon beta-1b), presented this week at the American Academy of Neurology’s (AAN) 59th Annual Meeting, demonstrating early efficacy, long-term tolerability, and high patient satisfaction with treatment in patients with relapsing forms of multiple sclerosis (MS).
Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced that the Company has received two U.S. Food and Drug Administration (FDA) approvals related to its ENJUVIA(TM) (synthetic conjugated estrogens, B) product.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that new data from the TOUCH Prescribing Program? and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI? (natalizumab). Also presented at the 59th annual meeting of the American Academy of Neurology in Boston, MA were extension study data that showed that TYSABRI has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis (MS) patients treated for up to three years.
A simple blood test ? beyond standard lab tests ? taken at hospital admission strongly predicted in-hospital mortality risk for heart failure patients and may be useful in helping doctors decide which patients need higher-level monitoring and more intensive treatment.
Parkinson’s disease is well-known for its progression of motor disorders: stiffness, slowness, tremors, difficulties walking and talking. Less well known is that Parkinson’s shares other symptoms with narcolepsy, a sleep disorder characterized by sudden and uncontrollable episodes of deep sleep, severe fatigue and general sleep disorder.
Negative pressure wound therapy is a new innovation in treating severe and complex wounds in children that decreases the need for frequent and stressful dressing changes. A new study in Wound Repair and Regeneration shows that this technique has a wide range of applications with children, and can be life-saving.
A new study in The American Journal of Gastroenterology suggests that smoking may determine which part of the intestinal tract is attacked in those who suffer from Crohn?s disease. Where the disease is located often determines whether the patient will eventually require surgical treatment.
A team led by UCSF scientists has received a grant of $15 million, provided over five years, to study the complex genetic factors that underlie some of the most common forms of epilepsy.
Advanced Cell Technology, Inc. (OTCBB: ACTC) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors–known as hemangioblasts–from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
Today, nearly 40 of the US’s top business leaders and largest employers joined forces to announce the formation of the Coalition to Advance Healthcare Reform (CAHR). Standing shoulder to shoulder with lawmakers at a Capitol Hill press conference, they discussed the coalition’s core principles, its mission and called for meaningful federal and state policy reforms by 2009 to solve the nation’s healthcare crisis.